Drug Res (Stuttg) 2020; 70(08): 376-384
DOI: 10.1055/a-1201-2700
Original Article

Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-obese Mice

Vishal Patel
1  Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
,
Amit Joharapurkar
1  Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
,
Samadhan Kshirsagar
1  Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
,
Maulik Patel
1  Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
,
Hardikkumar Savsani
1  Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
,
Rajesh Bahekar
1  Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
,
Mukul Jain
1  Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India
› Institutsangaben

Abstract

Background Obesity and diabetes are major metabolic disorders that progress to severe morbidity and mortality. Neuroendocrine mechanisms controlling energy balance indicate that combination therapies are needed to sustain weight loss. Lorcaserin was one of the approved therapies for the treatment of obesity, which is recently withdrawn because a safety clinical trial, shows an increased occurrence of cancer. Coagonist of glucagon-like-peptide-1 (GLP-1) and glucagon receptors is a novel investigational therapy demonstrated to have both anti-obesity and anti-diabetic effect. Here, we investigated the effect of combination of lorcaserin and a GLP-1 and glucagon receptors coagonist in diet-induced obese (DIO) mice model.

Methods The diet-induced obese C57BL/6J mice were used to assess acute and chronic effect of lorcaserin, coagonist of GLP-1and glucagon receptors and their combination on food intake, body weight, and biochemical parameters.

Results In acute study, combination of lorcaserin and coagonist causes synergistic reductions in food intake and body weight. Repeated treatment of combination of lorcaserin and coagonist showed enhanced body weight loss over time, which is due to reduction in fat mass (subcutaneous, retroperitoneal, mesenteric and epididymal fat pad) compared to individual therapy. Also, suppression of locomotor activity seen with lorcaserin was not evident in combination with coagonist. No additive effect was observed in glucose tolerance (intraperitoneal glucose tolerance test or insulin tolerance test), serum lipids, hepatic lipids, and energy expenditure in combination group.

Conclusion These data suggest that combination of lorcaserin and coagonist could be a better combination to induce body weight loss.



Publikationsverlauf

Eingereicht: 22. Mai 2020

Angenommen: 15. Juni 2020

Publikationsdatum:
09. Juli 2020 (online)

© Georg Thieme Verlag KG
Stuttgart · New York